Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
- Posted on July 23, 2026
- By CNBC
- 0 Views
- 1 min read
In brief
Generating AI summary…
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
